Zura Bio (ZURA) Competitors

Mesoblast (NASDAQ:MESO) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Does the MarketBeat Community believe in MESO or ZURA?

Mesoblast received 393 more outperform votes than Zura Bio when rated by MarketBeat users. However, 100.00% of users gave Zura Bio an outperform vote while only 71.23% of users gave Mesoblast an outperform vote.

Company	Underperform	Outperform
Mesoblast	Outperform Votes 401 71.23%	Underperform Votes 162 28.77%
Zura Bio	Outperform Votes 8 100.00%	Underperform Votes No Votes

Do insiders and institutionals have more ownership in MESO or ZURA?

2.6% of Mesoblast shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 15.8% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Do analysts rate MESO or ZURA?

Mesoblast presently has a consensus target price of $7.13, suggesting a potential upside of 393.08%. Zura Bio has a consensus target price of $16.60, suggesting a potential upside of 265.64%. Given Zura Bio's higher possible upside, equities analysts clearly believe Mesoblast is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Zura Bio	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

Which has preferable valuation and earnings, MESO or ZURA?

Zura Bio has lower revenue, but higher earnings than Mesoblast.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$7.50M	31.05	-$81.89M	-$0.56	-2.55
Zura Bio	N/A	N/A	$3.55M	N/A	N/A

Which has more volatility & risk, MESO or ZURA?

Mesoblast has a beta of 3.39, meaning that its share price is 239% more volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.

Is MESO or ZURA more profitable?

Zura Bio has a net margin of 0.00% compared to Zura Bio's net margin of -1,061.43%. Zura Bio's return on equity of -16.32% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	-1,061.43%	-16.32%	-12.26%
Zura Bio	N/A	-74.71%	-38.33%

Does the media prefer MESO or ZURA?

In the previous week, Mesoblast had 4 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for Mesoblast and 1 mentions for Zura Bio. Mesoblast's average media sentiment score of 1.35 beat Zura Bio's score of -0.45 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Mesoblast	Neutral
Zura Bio	Positive

Summary

Mesoblast beats Zura Bio on 9 of the 16 factors compared between the two stocks.